According to the official website of the State Food and drug administration, recently, the State Food and Drug Administration approved the listing of class 1 innovative drug fenaridone tablets (trade name: keshenda /kerendia). It is reported that this drug is suitable for adult patients with chronic kidney disease related to type 2 diabetes (estimated glomerular filtration rate [egfr]bd0de973c2c66cbf0c08923b2486529.png25 to lt; 75 ml/min/1.73 m2, with albuminuria), and can reduce the risk of continuous decline in EGFR and end-stage renal disease. Feneridone is a non steroidal, selective mineralocorticoid receptor (MR) antagonist. MR is expressed in kidney, heart and blood vessels. Fenaridone can reduce the inflammation and fibrosis mediated by Mr over activation. The launch of this drug provides a new treatment option for adult patients with type 2 diabetes related chronic kidney disease. In addition, the State Food and Drug Administration recently approved the listing of revlumide tablets (trade name: Irene), a class 1 innovative drug, through the priority review and approval procedure with conditions. The drug is suitable for patients with metastatic hormone sensitive prostate cancer (mhspc) with high tumor load. Revlumide is an androgen receptor (AR) inhibitor, which can competitively inhibit androgen binding to AR, thus inhibiting ar nuclear translocation and DNA binding, and reducing ar mediated gene transcription. The listing of this variety provides a new treatment option for patients with prostate cancer. (outlook new era)